Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Citius PharmaceuticalsSTU:47N0 25 Days Inventory is 6,233.02 as of Mar. 2026. GuruFocus rates STU:47N0 with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 637 Biotechnology companies, Citius Pharmaceuticals ranks worse than 98.27% on this metric.
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Citius Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.01.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Citius Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 13.50.
Citius Pharmaceuticals (STU:47N0) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Citius Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Citius Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Citius Pharmaceuticals Days Inventory Related Terms
Citius Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Citius Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:47N0 vs LEXX, HIND, PTN: Days Inventory Comparison
For the Biotechnology subindustry, Citius Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Citius Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Pharmaceuticals (STU:47N0) has a Days Inventory of 6,233.02 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Citius Pharmaceuticals and its competitors. According to the industry distribution chart, Citius Pharmaceuticals ranks #626 out of 637 companies in the Biotechnology industry, placing it in the top 98.3%.
Is Citius Pharmaceuticals' Days Inventory too high?
Citius Pharmaceuticals' current Days Inventory is 6,233.02. The Biotechnology industry median Days Inventory is 181.41. Citius Pharmaceuticals' value of 6,233.02 is 3335.9% above this industry median. Based on the distribution chart, Citius Pharmaceuticals ranks #626 out of 637 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Citius Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Citius Pharmaceuticals' Days Inventory compare to LEXX and HIND?
According to the Biotechnology industry distribution chart, Citius Pharmaceuticals ranks #626 out of 637 companies for Days Inventory. This places Citius Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 181.41. Citius Pharmaceuticals' value of 6,233.02 is 3335.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 181.41, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Pharmaceuticals's current Days Inventory of 6,233.02 is 3335.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Citius Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 181.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Pharmaceuticals's current Days Inventory is 6,233.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Pharmaceuticals stock overvalued right now?
Citius Pharmaceuticals (STU:47N0) has a current Days Inventory of 6,233.02. The current Days Inventory is 6,233.02 and 3335.9% above the Biotechnology industry median of 181.41. Citius Pharmaceuticals' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Citius Pharmaceuticals (STU:47N0), the current Days Inventory is 6,233.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
25GF Score
Get the complete analysis for STU:47N0
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:47N0 has been successfully added to your 
